The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions

Details for Australian Patent Application No. 2005203196 (hide)

International Classifications

Event Publications

4 August 2005 Complete Application Filed

18 August 2005 Application Open to Public Inspection

Published as AU-B-2005203196

25 August 2005 Corrigenda

Complete Applications Filed - Name Index Under the name SmithKline Beecham Corporation and Laboratoire GlaxoSmithKline S.A.S., Application No. 2005203196, under INID (71) correct the name to read Glaxo Group Limited, SmithKline Beecham Corporation and Laboratoire GlaxoSmithKline S.A.S.

24 November 2005 Assignment before Grant

Laboratoire GlaxoSmithKline S.A.S.; SmithKline Beecham Corporation; Glaxo Group Limited The application has been assigned to Glaxo Group Limited; Laboratoire GlaxoSmithKline S.A.S.

17 August 2006 Amendment Made

The nature of the amendment is: Delete the co-inventor Patel, Bela Rajiv

29 January 2009 Application Accepted

Published as AU-B-2005203196

28 May 2009 Standard Patent Sealed

1 March 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.